Target Name: TMPO-AS1
NCBI ID: G100128191
Review Report on TMPO-AS1 Target / Biomarker Content of Review Report on TMPO-AS1 Target / Biomarker
Other Name(s): TMPO antisense RNA 1

Introduction to TMPO-AS1

TMPO-AS1 (Thymopoietin antisense 1) is a long non-coding RNA (lncRNA) that has recently gained attention as a potential drug target or biomarker in various diseases. This article aims to provide an overview of TMPO-AS1, its associated functions, and its potential implications in diseases, highlighting its significance in the medical field.

The Role of TMPO-AS1:

TMPO-AS1 is transcribed from the TMPO gene and is located on chromosome 12q24.31. Unlike protein-coding genes, lncRNAs do not encode proteins but have crucial roles in gene regulation and cellular processes. TMPO-AS1 has been identified as a critical regulator in cellular processes such as cell cycle control, differentiation, apoptosis, and genomic stability.

Significance as a Drug Target:

The dysregulation of TMPO-AS1 expression has been implicated in several diseases, making it a potential target for therapeutic interventions. For example, in cancer research, TMPO-AS1 has been found to be upregulated in various types of tumors, including colorectal, breast, and lung cancer. It promotes cancer progression by modulating cell proliferation, invasion, and metastasis. Targeting TMPO-AS1 with gene silencing techniques, such as RNA interference or antisense oligonucleotides, holds promising potential for developing novel cancer therapies.

Diagnostic and Prognostic Biomarker:

Besides being a potential drug target, TMPO-AS1 has also shown promise as a diagnostic and prognostic biomarker. In colorectal cancer, elevated expression of TMPO-AS1 has been identified as a potential diagnostic marker, enabling earlier detection of the disease. Furthermore, high TMPO-AS1 levels have been correlated with poor survival rates and disease progression in several cancer types, suggesting its prognostic value. Its use as a biomarker may aid in personalized medicine by facilitating early intervention and predicting treatment response.

Regulatory Mechanisms:

The molecular mechanisms underlying the functions of TMPO-AS1 are still being unraveled. However, several studies have revealed its involvement in gene regulation. TMPO-AS1 has been found to interact with chromatin-modifying enzymes, transcription factors, and microRNAs (miRNAs). It can act as a competing endogenous RNA (ceRNA), sequestering specific miRNAs and preventing their binding to target mRNAs. This ceRNA activity of TMPO-AS1 can regulate gene expression networks and influence cellular processes.

Potential Therapeutic Applications:

The identified functions and dysregulation of TMPO-AS1 in various diseases highlight its potential therapeutic applications. Besides its role in cancer, TMPO-AS1 has also been implicated in other pathologies. For instance, in cardiovascular diseases, it has been shown to modulate cardiac fibrosis by interacting with fibrotic-related genes. Additionally, TMPO-AS1 has been associated with neurodegenerative disorders such as Alzheimer's and Parkinson's diseases. Manipulating its expression or activity could potentially ameliorate pathological processes in these conditions.


In conclusion, TMPO-AS1 is an emerging player in disease pathogenesis and offers exciting opportunities as a drug target and biomarker. Its involvement in diverse cellular processes and dysregulation in various diseases highlight its potential therapeutic applications. Further research is required to elucidate the molecular mechanisms of TMPO-AS1 and explore its therapeutic potential fully. However, its ability to regulate gene expression networks and serve as a diagnostic and prognostic biomarker makes TMPO-AS1 a promising candidate for future clinical applications.

Protein Name: TMPO Antisense RNA 1

The "TMPO-AS1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about TMPO-AS1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at

More Common Targets

TMPRSS6 | TMX2-CTNND1 | TMX3 | TNF | TNFAIP8L2-SCNM1 | TNIP2P1 | TNK2-AS1 | TNPO2 | TOB1 | TOGARAM2 | TOLLIP | TOM1 | TOM1L1 | TOMM6 | TOMM7 | TONSL-AS1 | TOR1A | TOR1AIP2 | TP53 | TP53TG3HP | TPBGL | TPCN1 | TPP1 | TPRG1-AS1 | TPRG1-AS2 | TPST2P1 | TPT1-AS1 | TPTE2P5 | Transfer RNA methionine (anticodon CAU) | Transmembrane protein FLJ37396 | TRAP1 | TRAPPC3L | TRDMT1 | TRE-TTC10-1 | TRE-TTC9-1 | TREM1 | TREM2 | TRERNA1 | TRF-GAA8-1 | TRG-AS1 | TRIM10 | TRIM28 | TRIM34 | TRIM44 | TRIM51G | TRIM59-IFT80 | TRIM6 | TRIM60 | TRIM60P15 | TRIM64 | Tripartite motif containing 78, pseudogene | TRIT1 | TRL-AAG1-2 | TRL-TAG2-1 | TRMT13 | TROAP | TRP-AGG6-1 | TRPC7-AS1 | TRPM4 | TRPM7 | TRPV3 | TSC22D3 | TSFM | TSNAX-DISC1 | TSPAN1 | TSPAN2 | TSPAN3 | TSPAN32 | TSPAN5 | TSPEAR | TSPEAR-AS1 | TSPO | TSPOAP1-AS1 | TSSC4 | TSTD1 | TSTD3 | TTC21A | TTC21B-AS1 | TTC24 | TTC3-AS1 | TTC34 | TTLL1-AS1 | TTLL8 | TTLL9 | TTN-AS1 | TUBA1B-AS1 | TUBB2BP1 | TUBB8P7 | TUNAR | TVP23C-CDRT4 | TWIST2 | TXLNB | TXN | TXNL1P1 | TXNP6 | TYMP | U2AF1L4 | UBA2 | UBAC2-AS1 | UBASH3A